



Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ E-mail: info@pharmacy.la.gov



BULLETIN No. 23-01

To: All pharmacies, pharmacists, interns, technicians, and technician candidates
From: Joe Fontenot, Executive Director
Date: July 31, 2023
Re: New Laws from 2023 Regular Session of Louisiana Legislature

During their 2023 Regular Session, the Louisiana Legislature passed new laws which will impact the practice of pharmacy or board operations. Most of the new laws will take effect on August 1, but there are some exceptions. A brief summary, with links, is presented here:

[Act 14](#) [effective 08-01-2023] amended the Prescription Monitoring Program (PMP) law reducing the frequency of mandatory advisory council meetings from quarterly to at least once annually and provides for the ability to meet by electronic means.

[Act 201](#) [effective 08-01-2023] updated the state list of controlled substances to include federal scheduling actions since the previous legislative session and provided for related matters. In Schedule I, several substances were added and the structural language for several compounds were updated to combat the new creative compounds that are being produced. In Schedule IV, *Daridorexant* was added to the list of depressants and *Fenfluramine* was removed from the schedule. In Schedule V, *Ganaxolone* was added to the list of depressants and the spelling of *Pregabalin* was corrected. Finally, *Amanita Pantherine* was added to the state list of unlawful hallucinogenic plants.

[Act 311](#) [effective 06-13-2023] amended the state medical marijuana law in regards to 1.) the transfer of membership interest in a marijuana pharmacy, 2.) the issuance of satellite pharmacy permits, and 3.) the meaning of "active, qualified patient".

Other Acts of interest:

[Act 358](#) [effective 08-01-2023] relative to the 340B drug pricing program.

[Act 281](#) [effective 08-01-2023] relative to smoking cessation benefits.

[Act 183](#) [effective 08-01-2023] relative to unlawful production, manufacturing, distribution, or possession of *Xylazine*.

[Act 322](#) [effective 01-01-2024] relative to "telehealth" services.

[Act 416](#) [effective 08-01-2023] relative to *Mitragynine* and *7-Hydroxymitragynine*.